^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

S095025

i
Other names: S095025, PRS-352
Associations
Trials
Company:
Pieris Pharmaceuticals, Servier
Drug class:
PD-L1 inhibitor, OX40 agonist
Related drugs:
Associations
Trials
over2years
The anticalin-antibody bispecific PRS-352/S095025 strongly stimulates human CD4+ T cells in a PD-L1-dependent manner (AACR 2022)
We provide here the preclinical characterization of the fusion protein PRS-352/S095025, a bispecific molecule composed of a PD-L1 blocking moiety and an Anticalin protein agonizing OX40. In vitro, this molecule showed the desired MoA, PD-L1 blocking and potent OX40 agonism driven by binding to PD-L1, with superior activity to a clinical stage OX40 agonist.
Late-breaking abstract • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
S095025